Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

Viking Therapeutics shows promise with weight loss drug VK2735 and potential in NASH treatment, making it a potential ...

The fully funded study is expected to evaluate TNF-a levels in patients receiving GLP-1 agonist Wegovy or Ozempic who show signals for increased inflammation associated with sarcopenia. TNFA is ...

And if you have any idea what that means, it might be too late for you. Fortnite is no stranger to collaborations, from ...

William Blair analyst Sami Corwin maintained a Buy rating on Neurogene (NGNE – Research Report) yesterday. The company’s shares opened today at ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a research note published on Monday morning. The brokerage issued a sell rating on the stock. A number ...

It's four o'clock in the morning and I've been walking in a tight circle in my bedroom, on-and-off, for three hours.

"Since our lead drug targets excess pro-inflammatory TNF-alpha, a primary cause of sarcopenia ... GLP-1 agonists are expected to be the top selling drug class in 2024. 2 The GLP-1 agonist market is ...

In its anniversary year, Germany’s most important research prize goes to four female researchers and six male researchers / €2.5 million in prize money ... of the cell membrane and the transport of ...

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients ...

Objective: To evaluate literature reporting on the role of norepinephrine in alcohol withdrawal and to determine the safety and efficacy of α 2-agonists in reducing symptoms of this severe condition.